Advisers to the FDA will debate if the virus has mutated enough since last winter to require a tweak to the formula.

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

If I am unable to access a vaccine in the future and get a nasty case of COVID, I'll know where to point the finger and so will millions of others.

The U.S. Food and Drug Administration’s decision to limit COVID vaccines to people 65 and older and others with underlying ...

A problem very rarely spoken about is the treatments that are promising, but are not developed further. Ben Hargreaves finds that these drug candidates are often left in limbo and never see the ...

Teva has asked the Supreme Court to look at a judgment in a $235 million patent dispute with GSK that it claims could undermine the ability of generic drugmakers to bring new products to market ...

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another ...

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...